ASX Announcements

Presentation at AusBiotech Invest and Partnering 2018
Appendix 4C - quarterly
Trofinetide ex-North America exclusive negotiation period
Neuren and ACADIA hold Rett syndrome SAB meeting
Change of Director's Interest Notice
FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID
Investor presentation, 6 September 2018
Half Yearly Report and Accounts
Neuren and Lanstead agree to pause settlements for 120 days
Appointment of auditor